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To expand the clinical and genetic spectrum of nemaline myopathy 10 by a series of Austrian
and German patients with a milder disease course and missense mutations in LMOD3.
Methods
We characterized the clinical features and the genetic status of 4 unrelated adolescent or adult
patients with nemaline myopathy.
Results
The 4 patients showed a relatively mild disease course. They all have survived into adulthood, 3
of 4 have remained ambulatory, and all showed marked facial weakness. Muscle biopsy
specimens gave evidence of nemaline bodies. All patients were unrelated but originated from
Austria (Tyrol and Upper Austria) and Southern Germany (Bavaria). All patients carried the
missense variant c.1648C>T, p.(Leu550Phe) in the LMOD3 gene, either on both alleles or in
trans with another missense variant (c.1004A>G, p.Gln335Arg). Both variants were not
reported previously.
Conclusions
In 2014, a severe form of congenital nemaline myopathy caused by disrupting mutations in
LMOD3 was identified and denoted as NEM10. Unlike the previously reported patients, who
had a severe clinical picture with a substantial risk of early death, our patients showed a relatively
mild disease course. As the missense variant c.1648C>T is located further downstream com-
pared to all previously published LMOD3mutations, it might be associated with higher protein
expression compared to the reported loss-of-function mutations. The apparent clusters of 2
mild mutations in Germany and Austria in 4 unrelated families may be explained by a founder
effect.
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Nemaline myopathy (NEM) is a genetically heterogeneous
congenital myopathy with the characteristic finding of
electron-dense “nemaline bodies” in myofibers. In 2014
twenty-one patients from 14 families with a severe form of
congenital NEM and disrupting mutations in LMOD3 (MIM
*616112) were reported.1 This form is denoted as NEM10
(MIM #616165). Following the first patients series, 2 further
families with fatal NEM10 were published.2,3
Here we describe 4 unrelated patients with clinically, ultra-
structurally, and genetically confirmed NEM10 based on 2
missensemutations within LMOD3 presenting with a hitherto
undescribed milder phenotype.
Methods
We reviewed the clinical features of 4 unrelated adolescent or
adult patients with nemaline myopathy. The LMOD3 muta-
tions were detected by whole exome sequencing in patients 1
and 2, and by next generation sequencing-based panel analysis
in patients 3 and 4. Histologic stains and transmission electron
microscopy were performed according to standard protocols.
Results
In contrast to previous reports, our patients showed a mild
disease course with pronounced facial weakness from birth but
mostly stable muscle function otherwise (figure 1). In patient 1
reduced fetal movements were reported. Patient 2 had a history
of intrauterine growth restriction and polyhydramnios resulting
in Cesarean delivery. Both patients showed an impaired neo-
natal respiratory adaption with resuscitation needed in patient
2. Pregnancy and delivery were normal in the remaining 2
patients. Severe weakness of facial, oral, and pharyngeal muscles
was present in all patients. All had swallowing difficulties after
birthmaking transient nasogastric tube feeding necessary in 3 of
them (table). All patients had dysarthric speech. When last
examined, no patient had swallowing difficulties, but chewing
was still not possible in patient 2.
Despite impaired postnatal adaptation and the presence of
muscular hypotonia from birth, our patients developed re-
markably well and stabilized during the first year of life. Motor
development was delayed in 2 patients: independent walking
was achieved at age 2 years in patient 1 and at the age of nearly 6
years in patient 2. Patients 3 and 4 walked independently from
the age of 16 and 14 months, respectively. Limb function was
affected in all patients with lower limb weakness and a milder
distally pronounced upper limb weakness. Patient 2 was non-
ambulatory from age 12 due to truncal weakness and progressive
thoracolumbar scoliosis. Patients 1, 3, and 4 were ambulatory at
ages 18, 20, and 30 years, although patient 1 was not able to run
and had difficulties in climbing stairs. Mild scoliosis was present
in patient 3. No patient had a clinically relevant respiratory
dysfunction; only patient 2 had a reduced forced vital capacity
(45%) in lung function tests at the age of 18 years.
Muscle biopsy specimens showedmultiple nemaline bodies in
Gomori trichrome stain. Transmission electron microscopy
demonstrated Z-line streaming and multiple nemaline rods
(figure 2).
The patients were offspring of 4 non-consanguineous couples
with Austrian (Tyrol and Upper Austria) or German (Bavaria)
provenance within a maximum geographical distance of ca.
300 km. Our patients shared 2 LMOD3 missense mutations
(NM_198271.4: c.1004A>G and c.1648C>T), either in ho-
mozygous or in compound heterozygous state (table). In all
families, segregation studies were performed confirming
Figure 1 Clinical phenotype of patients with NEM10 and
LMOD3 mutations
(A) Patient 2 at the age of nearly 6 years presenting with an elongated face,
and severe facial and jaw weakness. (B) Patient 3 at age 20 years with
a symmetrical deep funnel chest with Harrison’s groove. (C and D) Patient 4
at age 30 years showing pronounced facial weakness with incomplete eye
closure.
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autosomal recessive inheritance. Both LMOD3 variants
(c.1004A>G, p.Gln335Arg and c.1648C>T, p.Leu550Phe) af-
fect amino acid residues that are highly conserved up to Xen-
opus and zebrafish and are not listed in the in-house database
(Munich Exome Server)4 nor in large reference datasets, such
as the ExAC or the gnomAD browsers. In silico prediction is
pathogenic according to MutationTaster, CADD, DANN, and
fathmm. Bothmutations are listed in ClinVar with an unknown
clinical significance after detection in patient 3.
Discussion
In contrast to the previously reported patients, who had a severe
clinical picture with a substantial risk of early death, our patients
showed a stable and muchmilder disease course. WhenNEM10
was genetically defined, the patients initially reported presented
with intrauterine manifestations: polyhydramnios (62%), de-
creased or absent fetalmovements (48%), arthrogryposis or joint
contractures (48%), or fetal edema.1 All patients had severe
muscular weakness and hypotonia with a fatal outcome in most
patients: 7 (33%) died from respiratory failure in the neonatal
period, 6 (29%) patients died during the first year of life, and one
pregnancy was terminated. Only 2 sisters were reported to be
alive at the time of publication (age 10 and 4 years), after prenatal
onset and a severe infantile disease course requiring gastrostomy
and nocturnal noninvasive ventilation.
In 2017, 3 siblings with NEM10, born to consanguineous
parents, due to the previously described frame-shift
mutation c.138dupC, p.Ser47Glnfs*13 were reported.2
They showed fetal hypokinesia, had congenital fractures of
long bones, and died of respiratory failure during early infancy.
Recently, 2 fetuses from one family have been reported with
a severe prenatal disease course especially encompassing absent
fetal movements and abnormal posturing.3 Genetic diagnosis
of NEM10 was made after pregnancy termination with both
fetuses being compound heterozygous for the previously un-
known frame-shift mutation p.Glu121Argfs*5 and the deletion
p.Leu245del in LMOD3, respectively (no transcript in-
formation has been provided for these mutations).
LMOD3 localizes mainly to the A band of the sarcomere5 and is
a key regulator of thin filament length in skeletal muscle.1 It
contains a tropomodulin-binding helix and 3 actin-binding
domains: actin-binding helix, leucine-rich repeat domain (LRR),
and Wiskott-Aldrich-syndrome protein homology 2 domain
(WH2).1 Most LMOD3 mutations known so far are loss of
function mutations. Protein expression analysis was performed
for ten of the 15mutations reported: protein expressionwas only
present in 2 milder affected siblings who were compound het-
erozygous for 2 nonsense mutations in the C-terminal region
of the LRR domain.1 There was no protein expression for
6 other nonsense mutations; inconclusive results were reported
for 2 mutations.1 Only one missense mutation (c.976G>C,
p.Gly326Arg) has been described so far. It was found in com-
bination with 2 different nonsense mutations, causing a severe
phenotype. The c.976G>C mutation lies within the LRR do-
main, as does the mutation c.1004A>G described here.
Table Clinical features and genotype of the 4 patients with NEM10
Patient 1 Patient 2 Patient 3 Patient 4
Age at last presentation, y 18 18 20 30
Sex Female Female Male Female
Age at onset Prenatal Prenatal Birth Birth
Apgar-score 4/5/7 3/3/5 7/8/9 8/9/9
Postnatal feeding problems + + (tube feeding until age 2
years)
+ (tube feeding until age 3
months)
+ (tube feeding until age 3
months)
Age at first walking 2 y 6 y 16 mo 14 mo
Ambulatory + − (From age 12 y) + +
Limb weakness (LL > UL) + + + +
Scoliosis − + (progressive) + (mild) −
Dysarthria and pronounced facial
weakness
+ + + +
Respiratory function Normal (age 15 years) Reduced (FVC 45%; age
18 y)
Normal (age 19 y) Normal (age 29 y)
LMOD3 genotype c.[1648C>T];[1648C>T] c.[1004A>G];[1648C>T] c.[1004A>G];[1648C>T] c.[1648C>T];[1648C>T]
Provenance Austria (Tyrol) Austria (Upper Austria) Germany (Bavaria) Austria (Tyrol)
Abbreviations: FVC = forced vital capacity; LL = lower limbs; UL = upper limbs.
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All 4 patients described in this study are homozygous or
compound heterozygous for the variant c.1648C>T. This
variant is located further downstream (within the WH2
domain) compared to all previously published LMOD3
mutations. The physicochemical difference of the affected
amino acid is predicted to be small in this mutation
(p.Leu550Phe) with a Grantham distance of 22, possibly
leading to a more tolerable molecular change in LMOD3.
The functional role for the WH2 domain in LMOD3 is not
known to date. In LMOD1 and LMOD2 the WH2 domain
acts as an actin binding domain, involved in actin nucleation,
an early step in actin polymerization.6 In these 2 other
LMOD proteins the equivalent to the LRR domain is the
main actin binding site. The WH2 domain itself is re-
sponsible for a 2 to 3-fold increase in actin nucleation ac-
tivity, and mutations within the WH2 domain are predicted
to have only a mild effect on this process. This is also sup-
ported by the observation that other domains in the
C-terminal region of LMOD2 might have a stronger func-
tional implication than the WH2 domain does. Hence, the
mutation c.1648C>T might be responsible for the milder
disease phenotype in the patients described here.
The observation of recurrent rare LMOD3 variants in patients
with a clinical and morphological phenotype matching NEM
supports the predictably pathogenic effect of the detected
mutations. The mutational spectrum in LMOD3 remains to
be further defined, but the apparent clusters of 2 mild muta-
tions in Germany and Austria in 4 unrelated families may be
explained by a founder effect.
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Figure 2 Muscle biopsies from 3 patients with NEM10 and LMOD3 mutations
(A) Gomori trichrome stain (patient 3 at the age of 14 years) shows marked nemaline bodies (arrows) in highly atrophic myofibers. (B and C) Transmission
electronmicroscopy images of patient 2 at the age of 3 weeks. (B) Large area of disorganizedmyofilaments, compatible with a core-like structure, containing
dispersed Z-bandmaterial (arrows). (C)Multiple rod-bodies in a very smallmuscle fiber. (D–F) Transmission electronmicroscopy images of patient 1 at the age
of 5 years. (D) Fiber displaying disturbed intrafusal filament texture andmultiple electron dense nemaline rod structures. (E) Detail of rod textures out of (D).
(F) Single rod-body spanning a sarcomere.
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